IVF — INVO Fertility, Inc.

Summary of INVO Bioscience Q2 2023 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: Total revenue for Q2 2023 was approximately $316,000, up 116% from $146,000 in Q2 2022.
• Service Revenue: 81% of Q2 revenue ($254,000) came from the Atlanta INVO Center, compared to $112,000 in the prior year.
• Combined Revenue from Clinics: Revenue from all three clinics totaled $712,000, a 145% increase from $291,000 year-over-year.
• Operating Expenses: Decreased to approximately $2.4 million from $2.8 million in the prior year due to lower personnel, marketing, and R&D costs.
• Adjusted EBITDA Loss: Improved to approximately $1.6 million from a loss of $2.2 million in the previous year.
• Cash Position: As of June 30, 2023, cash was approximately $112,000 with $1.3 million in debt. The company raised approximately $4.5 million in a public offering.

2. Strategic Updates and Business Highlights:

• Acquisition: INVO completed the acquisition of the Wisconsin Fertility Institute, which had revenues of over $5 million and net income of approximately $1.7 million last year. This acquisition is expected to double the run rate of clinic operations and significantly enhance profitability.
• Clinic Expansion: The company is set to open a new INVO Center in Tampa within 60 to 90 days, following the successful establishment of centers in Birmingham and Atlanta.
• Product Development: INVOcell received FDA 510(k) clearance for a five-day incubation period, which is anticipated to improve patient outcomes and enhance competitive positioning.
• Transition Focus: The company is transitioning from a medical device manufacturer to a healthcare services provider in the fertility market.

3. Forward Guidance and Outlook:

• INVO aims to achieve operating cash flow breakeven in 2024, supported by the integration of the Wisconsin clinic and the opening of the Tampa center.
• The company expects continued revenue growth from existing clinics and the inclusion of Wisconsin's results in future financial statements.

4. Bad News, Challenges, or Points of Concern:

• Cash Reserves: The company has a limited cash position, which may pose challenges for operational flexibility.
• Market Competition: There is ongoing competitive pressure from traditional IVF clinics, which have historically communicated lower success rates for INVOcell technology. The company aims to overcome this with improved messaging following the recent FDA clearance.
• Cost Management: While operating expenses have decreased, the integration of the Wisconsin clinic will add costs, although they are expected to be profitable.

5. Notable Q&A Insights:

• The FDA's five-day incubation approval is seen as a significant competitive advantage, allowing better marketing and improved patient outcomes.
• Management clarified that the breakeven target for 2024 does not factor in additional acquisitions, focusing instead on organic growth from existing operations.
• Cost reductions of approximately 30% in corporate expenses have been implemented, which should support improved profitability moving forward.

Overall, INVO Bioscience is positioned for growth through strategic acquisitions and operational improvements, despite facing competitive challenges and a constrained cash position.